USE IN PREGNANCY
When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, enalaprilat injection should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.
Enalaprilat Injection is a sterile aqueous solution for intravenous administration. Enalaprilat is an angiotensin converting enzyme inhibitor.
Enalaprilat Injection is indicated for the treatment of hypertension when oral therapy is not practical.
Enalaprilat Injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension.
In using Enalaprilat Injection, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that Enalaprilat Injection does not have a similar risk. (See WARNINGS.)
In considering use of Enalaprilat Injection, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema.)
Media Articles Related to Enalaprilat
Low levels of hormone in African-Americans may increase hypertension
Source: Endocrinology News From Medical News Today [2015.06.11]
Although hypertension is more common in African-Americans, they have significantly lower levels of a hormone produced in response to cardiac stress than white and Hispanic individuals, a finding that...
Source: MedicineNet Alcohol Abuse and Alcoholism Specialty [2015.05.29]
Title: Portal Hypertension
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 5/29/2015 12:00:00 AM
New data show need for improved monitoring for pulmonary hypertension following pulmonary embolism
Source: Hypertension News From Medical News Today [2015.05.20]
Results from a retrospective cohort study presented at the American Thoracic Society (ATS) 2015 International Conference in Denver found that the incidence of pulmonary hypertension (PH) among...
Source: MedicineNet Fainting Specialty [2015.02.19]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 2/19/2015 12:00:00 AM
Picture of Hypertension
Source: MedicineNet Renal Artery Stenosis Specialty [2014.12.09]
Title: Picture of Hypertension
Created: 2/3/2011 1:47:00 PM
Last Editorial Review: 12/9/2014 12:00:00 AM
Published Studies Related to Enalaprilat
Myocardial protection with enalaprilat in patients unresponsive to ischemic preconditioning during percutaneous coronary intervention. [2008.12]
Cardioprotection due to angiotensin enzyme inhibitors is attributed, at least in part, to the inhibition of bradykinin breakdown and the preconditioning effect of the elevated endogenous bradykinin level. We have previously shown that in patients undergoing percutaneous coronary intervention, one 120-second balloon inflation is insufficient to precondition the heart...
Pretreatment with intracoronary enalaprilat protects human myocardium during percutaneous coronary angioplasty. [2007.04.17]
OBJECTIVES: We tested the hypothesis that enalaprilat induces preconditioning (PC)-mimetic actions in patients with stable coronary artery disease. BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors increase the bioavailability of bradykinin, which induces cardiac PC... CONCLUSIONS: Pretreatment with enalaprilat attenuates the manifestations of myocardial ischemia during angioplasty. This is the first in vivo evidence showing that an ACE inhibitor protects human myocardium, possibly via PC-mimetics actions, a novel property that might explain the cardioprotective actions of these drugs.
Clinical Trials Related to Enalaprilat
Comparison of the Antihypertensive Efficacy of Valsartan and Enalapril After Missing One Dose [Completed]
This study was designed in order to evaluate the blood pressure lowering effect of valsartan
compared to enalapril over 24 hours after skipping one daily dose. Both drugs act on the
renin-angiotensin-aldosterone system (RAAS) and are widely use for the treatment of
hypertension. Previous studies had a significant limitation: the effect of a missing dose was
not evaluated after the whole 24 hours post missing dose period (48 hours after last taken
dose), and as a result, it does not imitate the real life situation of a missing dose.
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure [Recruiting]
The study will evaluate the efficacy and safety of both aliskiren monotherapy and
aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity
and mortality in patients with chronic heart failure (NYHA Class II - IV.
Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension [Recruiting]
The poupose of this study is to evaluate the efficacy and safety of various dosage
combinations of lercanidipine (10 and 20 mg)and enalapril (10 and 20 mg) in comparison with
their respective components and with placebo.
Effect of Enalapril Plus Folic Acid on Blood Pressure and Glycometabolism [Completed]
Combinded therapy with folic acid and enalapril may significantly decrease plasma total
homocysteine level and had beneficial effect on blood pressure reduction and
Drug Interaction Study of Avanafil and Enalapril or Amlodipine [Recruiting]
The purpose of this study is to determine the change in the blood pressure and pulse rate,
pharmacokinetics and the safety when avanafil is taken with either enalapril or amlodipine.